닫기
18.97.14.84
18.97.14.84
close menu
Two cases of treatment with carvedilol for erythematotelangiectatic rosacea
( Min Song Suh ) , ( Sook Jung Yun ) , ( Young Ho Won ) , ( Jee Bum Lee )
UCI I410-ECN-0102-2017-510-000081496
This article is 4 pages or less.

Erythematotelangiectatic rosacea (ETR) is characterized by persistent facial flushing, telangiectasia and erythema, which may be accompanied by facial edema, burning or stinging. Oral agents including tetracycline, isotretinoin, and acetylsalicylic acid are used for improving flushing and erythema. However, severe facial flushing and erythema still remains challenging despite oral agents such as contraceptives, propranolol, and β-adrenergic blocker. Herein, we report two cases of ETR who were unresponsive to conventional treatments, eventually improved with carvedilol, a nonselective β-adrenergic blocker. A 64-year-old man and a 49-year-old woman presented with persistent facial flushing and erythema. Both patients were treated with minocycline, acetylsalicylic acid, and topical metronidazole gel with no improvement. We added carvedilol (3.125 mg, once a day) to each patient``s current agents. The severity of facial flushing and erythema with telangiectasia was evaluated by clinical photographs and the patient``s subjective contentment using a 5-point-scoring system after treatment. Significant improvement of facial symptoms was observed within about 4 weeks. The patient``s assessment of the symptoms showed high satisfaction. During treatment, no side effects were found. In conclusion, we consider low-dose carvedilol as a safe and effective in the treatment of refractory ETR patients.

[자료제공 : 네이버학술정보]
×